DE69533855D1 - UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG - Google Patents
UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNGInfo
- Publication number
- DE69533855D1 DE69533855D1 DE69533855T DE69533855T DE69533855D1 DE 69533855 D1 DE69533855 D1 DE 69533855D1 DE 69533855 T DE69533855 T DE 69533855T DE 69533855 T DE69533855 T DE 69533855T DE 69533855 D1 DE69533855 D1 DE 69533855D1
- Authority
- DE
- Germany
- Prior art keywords
- binding
- mdm2
- interruption
- therapeutic application
- corresponding therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US277660 | 1994-07-20 | ||
US08/277,660 US5702908A (en) | 1994-07-20 | 1994-07-20 | Interruption of binding of MDM2 and p53 protein and therapeutic application thereof |
US08/424,957 US5770377A (en) | 1994-07-20 | 1995-04-19 | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
US424957 | 1995-04-19 | ||
PCT/GB1995/001719 WO1996002642A1 (en) | 1994-07-20 | 1995-07-20 | INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69533855D1 true DE69533855D1 (de) | 2005-01-20 |
DE69533855T2 DE69533855T2 (de) | 2005-12-08 |
Family
ID=26958629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69533855T Expired - Fee Related DE69533855T2 (de) | 1994-07-20 | 1995-07-20 | UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG |
Country Status (9)
Country | Link |
---|---|
US (2) | US5770377A (de) |
EP (1) | EP0773996B1 (de) |
JP (2) | JP3961015B2 (de) |
AT (1) | ATE284959T1 (de) |
AU (1) | AU684194B2 (de) |
CA (1) | CA2195533A1 (de) |
DE (1) | DE69533855T2 (de) |
NZ (1) | NZ289899A (de) |
WO (1) | WO1996002642A1 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2738151B1 (fr) * | 1995-09-04 | 1997-09-26 | Rhone Poulenc Rorer Sa | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers |
WO1997011367A1 (en) * | 1995-09-18 | 1997-03-27 | Novartis Ag | ASSAY FOR IDENTIFYING INHIBITORS OF THE INTERACTION BETWEEN PROTEINS p53 AND dm2 |
US7083983B2 (en) * | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
GB9620028D0 (en) * | 1996-09-26 | 1996-11-13 | Ludwig Inst Cancer Res | Factors which interact with oncoproteins |
GB9708092D0 (en) * | 1997-04-22 | 1997-06-11 | Univ Dundee | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
GB9708089D0 (en) * | 1997-04-22 | 1997-06-11 | Univ Dundee | Materials and methods relating to stabilising substances in cells |
US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
US6372490B1 (en) * | 1999-02-23 | 2002-04-16 | Curagen Corporation | Nucleic acid encoding the MDM interacting protein |
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US20050245451A1 (en) * | 2000-04-05 | 2005-11-03 | Pincus Matthew R | Peptides selectively lethal to malignant and transformed mammalian cells |
US20040038902A1 (en) * | 2000-04-05 | 2004-02-26 | Pincus Matthew R. | Peptides selectively lethal to malignant and transformed mammalian cells |
US6989239B2 (en) * | 2001-06-20 | 2006-01-24 | R.E.D. Laboratories, N.V./S.A. | Methods for diagnosis and treatment of chronic immune diseases |
US20020169730A1 (en) * | 2001-08-29 | 2002-11-14 | Emmanuel Lazaridis | Methods for classifying objects and identifying latent classes |
WO2003105880A1 (en) * | 2002-03-12 | 2003-12-24 | The Research Foundation Of The State University Of New York | Peptides selectively lethal to malignant and transformed mammalian cells |
US7534861B2 (en) * | 2003-01-10 | 2009-05-19 | Ambergen, Inc. | Compositions and methods for immunoaffinity purification |
JP4051327B2 (ja) * | 2003-09-19 | 2008-02-20 | 新科實業有限公司 | 垂直磁気記録ヘッドおよびその製造方法、ならびに磁気記録装置 |
ES2586387T3 (es) | 2003-11-05 | 2016-10-14 | Dana-Farber Cancer Institute, Inc. | Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular |
WO2005074521A2 (en) * | 2004-01-30 | 2005-08-18 | The Trustees Of Columbia University In The City Of New York | C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF |
WO2005097820A1 (en) * | 2004-04-06 | 2005-10-20 | Korea Research Institute Of Bioscience And Biotechnology | Peptides for inhibiting mdm2 function |
JP2008501315A (ja) * | 2004-04-22 | 2008-01-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Hdm2阻害剤複合体およびそれらの使用 |
US7960506B2 (en) | 2006-12-14 | 2011-06-14 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
PT2118123E (pt) | 2007-01-31 | 2016-02-10 | Harvard College | Péptidos de p53 estabilizados e suas utilizações |
CN109627287A (zh) | 2007-02-23 | 2019-04-16 | 爱勒让治疗公司 | ***大环*** |
WO2008121767A2 (en) | 2007-03-28 | 2008-10-09 | President And Fellows Of Harvard College | Stitched polypeptides |
EP2224961A1 (de) * | 2007-11-26 | 2010-09-08 | The Research Foundation of the State University of New York | Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen |
BRPI0907754A2 (pt) * | 2008-02-08 | 2015-07-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos terapêuticos |
US20110144303A1 (en) * | 2008-04-08 | 2011-06-16 | Aileron Therapeutics, Inc. | Biologically Active Peptidomimetic Macrocycles |
EP2310407A4 (de) * | 2008-04-08 | 2011-09-14 | Aileron Therapeutics Inc | Biologisch wirksame peptidomimetische makrozyklen |
WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
EP2342221B1 (de) | 2008-09-22 | 2018-11-07 | Aileron Therapeutics, Inc. | Verfahren zur herstellung aufgereinigter polypeptidzusammensetzungen |
JP2012515172A (ja) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
CA2768299C (en) | 2009-07-13 | 2018-03-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
JP2013505300A (ja) | 2009-09-22 | 2013-02-14 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
KR101220516B1 (ko) | 2010-01-21 | 2013-01-10 | 연세대학교 산학협력단 | 항-mdm2를 발현하는 인간 성체줄기세포 및 그의 용도 |
RU2582678C2 (ru) | 2010-08-13 | 2016-04-27 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы |
US8957026B2 (en) | 2010-09-22 | 2015-02-17 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
WO2012174423A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of rab gtpase function |
TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
JP6450191B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス,インコーポレイテッド | ペプチドミメティック大環状化合物 |
EP2819688A4 (de) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | Triazol- und thioethervernetzte peptidomimetische makrozyklen |
RS61957B1 (sr) | 2012-09-26 | 2021-07-30 | Harvard College | Uvezani peptidi blokirani prolinom i njihove upotrebe |
WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
CA2909620A1 (en) | 2013-03-13 | 2014-10-02 | President And Fellows Of Harvard College | Stapled and stitched polypeptides and uses thereof |
EP3008081B1 (de) | 2013-06-14 | 2017-08-30 | President and Fellows of Harvard College | Stabilisierte polypeptid-insulinrezeptor-modulatoren |
JP6759109B2 (ja) | 2014-05-21 | 2020-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Ras抑制性ペプチドおよびその使用 |
KR20170058424A (ko) * | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
KR102570210B1 (ko) | 2014-09-24 | 2023-08-23 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 제제 |
KR101652894B1 (ko) * | 2014-12-18 | 2016-09-02 | 가천대학교 산학협력단 | 대장암에 대한 신규 바이오마커 및 그의 용도 |
JP2018516844A (ja) | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | ペプチド模倣大環状分子およびその使用 |
WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US9765117B2 (en) | 2015-08-24 | 2017-09-19 | Romek Figa | Peptides for treating cancer |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
CN111491661A (zh) * | 2017-07-27 | 2020-08-04 | 诺莫坎制药有限责任公司 | M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途 |
US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
AU4544393A (en) * | 1992-06-26 | 1994-01-24 | Trustees Of Princeton University, The | Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes |
WO1994008241A1 (de) * | 1992-09-30 | 1994-04-14 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | NACHWEISVERFAHREN FÜR p53-SPEZIFISCHE ANTIKÖRPER |
FR2698367B1 (fr) * | 1992-11-02 | 1995-02-17 | Eurobio Lab | Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques. |
US5532348A (en) * | 1993-07-30 | 1996-07-02 | United States Of America | E6 associated protein and methods of use thereof |
-
1995
- 1995-04-19 US US08/424,957 patent/US5770377A/en not_active Expired - Fee Related
- 1995-07-20 DE DE69533855T patent/DE69533855T2/de not_active Expired - Fee Related
- 1995-07-20 AU AU29876/95A patent/AU684194B2/en not_active Ceased
- 1995-07-20 EP EP95925934A patent/EP0773996B1/de not_active Expired - Lifetime
- 1995-07-20 JP JP50484096A patent/JP3961015B2/ja not_active Expired - Fee Related
- 1995-07-20 AT AT95925934T patent/ATE284959T1/de not_active IP Right Cessation
- 1995-07-20 WO PCT/GB1995/001719 patent/WO1996002642A1/en active IP Right Grant
- 1995-07-20 NZ NZ289899A patent/NZ289899A/xx unknown
- 1995-07-20 CA CA002195533A patent/CA2195533A1/en not_active Abandoned
-
1998
- 1998-03-05 US US09/035,686 patent/US6153391A/en not_active Expired - Fee Related
-
2007
- 2007-02-23 JP JP2007043694A patent/JP2007222170A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US5770377A (en) | 1998-06-23 |
DE69533855T2 (de) | 2005-12-08 |
CA2195533A1 (en) | 1996-02-01 |
EP0773996B1 (de) | 2004-12-15 |
AU2987695A (en) | 1996-02-16 |
JP2007222170A (ja) | 2007-09-06 |
ATE284959T1 (de) | 2005-01-15 |
JP3961015B2 (ja) | 2007-08-15 |
EP0773996A1 (de) | 1997-05-21 |
US6153391A (en) | 2000-11-28 |
JPH10506525A (ja) | 1998-06-30 |
AU684194B2 (en) | 1997-12-04 |
NZ289899A (en) | 2000-08-25 |
WO1996002642A1 (en) | 1996-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69533855D1 (de) | UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG | |
HUP9904023A2 (hu) | Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban | |
ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
ATE275383T1 (de) | Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen | |
ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
DE69324487T2 (de) | Rezeptorbindende region des diphtherietoxius | |
DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
DK0942740T3 (da) | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme | |
ATE230757T1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
ATE342278T1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
DE29602789U1 (de) | Liege, Decke o.dgl. zur therapeutischen Behandlung von Lebewesen | |
DE69531004D1 (de) | p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES | |
ATE290315T1 (de) | Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits | |
DE69534325D1 (de) | Peptide zur behandlung von krebs | |
DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
DE69805305T2 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE69834937D1 (de) | Antibiotika zur behandlung von magengeschwuren | |
ATE181240T1 (de) | Verwendung von somatostatinanalogen zur behandlung von melanomen | |
ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
DE69408394T2 (de) | 4-Piperidino-piperidin zur Behandlung von Tumoren | |
DE69715668D1 (de) | N-(pyridinylamino)isoindoline und verwandte verbindungen | |
ATE295731T1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
DE68908445T2 (de) | Mittel zur Behandlung von Lebererkrankungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |